Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5789 for Lamellar Ichthyosis (phase 2, Sweden)
2013-001796-20Phase 2Terminated
- Sponsor
- Galderma
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trifarotene in lamellar ichthyosis (LI), sponsored by Galderma. Primary endpoint: Primary efficacy endpoint. Started Jul 2013; status: terminated.
02
Drugs
trifarotene
03
Conditions
lamellar ichthyosis (LI)
Beyond the preview
Go deeper on 2013-001796-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001796-20.